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SHEA Position Paper
Influenza causes substantial morbidity and mortality 
annually, particularly in high-risk groups such as the elderly, 
young children, immunosuppressed individuals, and individu-
als with chronic illnesses. Healthcare-associated transmission 
of influenza contributes to this burden but is often under-rec-
ognized except in the setting of large outbreaks. The Centers 
for Disease Control and Prevention has recommended annual 
influenza vaccination for healthcare workers (HCWs) with di-
rect patient contact since 1984 and for all HCWs since 1993. The 
rationale for these recommendations is to reduce the chance 
that HCWs serve as vectors for healthcare-associated influ-
enza due to their close contact with high-risk patients and to 
enhance both HCW and patient safety. Despite these recommen-
dations as well as the effectiveness of interventions designed 
to increase HCW vaccination rates, the percentage of HCWs 
vaccinated annually remains unacceptably low. Ironically, at the 
same time that campaigns have sought to increase HCW vacci-
nation rates, vaccine shortages, such as the shortage during the 
2004–2005 influenza season, present challenges regarding allo-
cation of available vaccine supplies to both patients and HCWs. 
This two-part document outlines the position of the Society for 
Healthcare Epidemiology of America on influenza vaccination 
for HCWs and provides guidance for the allocation of influenza 
vaccine to HCWs during a vaccine shortage based on influenza 
transmission routes and the essential need for a practical and 
adaptive strategy for allocation. These recommendations apply 
to all types of healthcare facilities, including acute care hospi-
tals, long-term–care facilities, and ambulatory care settings (In-
fect Control Hosp Epidemiol 2005;26:882-890).
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Influenza Vaccination of Healthcare Workers and 
Vaccine Allocation for Healthcare Workers During 
Vaccine Shortages
Thomas R. Talbot, MD, MPH; Suzanne F. Bradley, MD; Sara E. Cosgrove, MD, MS; Christian Ruef, MD;  
Jane D. Siegel, MD; David J. Weber, MD, MPH
PART I: INFLUENZA VACCINATION OF 
HEALTHCARE WORKERS (HCWS)
Rationale
Influenza infection causes an average of 36,000 ex-
cess deaths and nearly 226,000 excess hospitalizations an-
nually in the United States alone.1,2 Contributing to this 
disease burden, influenza can be transmitted in healthcare 
settings from patient to patient, visitor to patient, patient 
to HCW, and HCW to patient. Healthcare-associated trans-
mission of influenza has been documented in many differ-
ent patient populations and clinical settings, including neo-
natal intensive care units,3-8 pediatric wards,9-12 adult and 
pediatric transplant units,13-16 infectious disease units,17,18 
general medical wards,19-21 geriatric wards and long-term–
care facilities,22-26 oncology units,27,28 pulmonary rehabili-
tation centers,29 and emergency departments.30 In many 
of these outbreaks, infections occurred in unvaccinated 
HCWs, and HCWs were linked epidemiologically to the 
transmission of influenza. Such healthcare-associated out-
breaks of influenza may result in increased patient mor-
bidity, mortality, length of hospitalization, and costs and 
may disrupt the essential services of a healthcare facility 
during a season when patient census and HCW absentee-
ism are high.19
Effective measures that can reduce the risk of 
healthcare-associated influenza during the influenza sea-
son include adherence to universal respiratory hygiene 
and cough etiquette practices, placement of patients with 
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influenza-like illness on droplet precautions at the point of 
first encounter, use of rapid diagnostic tests for patients 
and HCWs with suspected influenza, prompt treatment 
of patients with diagnosed influenza, provision of antiviral 
chemoprophylaxis for HCWs and patients under selected 
conditions, and restriction of ill HCWs from patient care. 
However, the cornerstone of efforts and the most effective 
measure to prevent healthcare-associated transmission of 
influenza is HCW vaccination with an effective influenza 
vaccine.31 
Influenza vaccination has been shown to reduce mor-
bidity, antibiotic use, and absenteeism in healthy adults32,33 
and to decrease serologically confirmed and clinical influen-
za, hospitalization for pneumonia and influenza, and mortality 
in the elderly.34 Influenza vaccination has also been effective 
in large studies specifically targeting HCWs (Fig. 1).35-39 In-
fluenza vaccination reduces influenza infection in HCWs by 
88%39 and decreases work absence due to respiratory illness 
by 28%.38 In two separate studies in geriatric long-term–care 
facilities, total patient mortality was significantly lower in 
those sites where HCWs were routinely vaccinated as com-
pared with sites where routine vaccination was not offered 
to HCWs (10% vs 17% and 14% vs 22%).36,37 Increased rates of 
HCW vaccination also correspond to a significant decrease 
in the incidence of healthcare-associated influenza.40 Admin-
istration of influenza vaccine to healthy children of various 
ages has been shown to decrease morbidity and mortality 
in their close contacts and in their communities, further sup-
porting the concept of immunizing HCWs to protect their 
high-risk contacts.41-45
Since 1984, the Advisory Committee on Immuni-
zation Practices of the Centers for Disease Control and 
Prevention (CDC) has strongly recommended annual in-
fluenza vaccination for HCWs to “protect [HCWs], their 
patients, and communities, [to] improve prevention of in-
fluenza-associated disease and patient safety, and [to] re-
duce disease burden.”31,46 Despite this recommendation, 
overall influenza vaccination rates in HCWs remain unac-
ceptably low, with only 40% of HCWs having received an 
influenza vaccination in 2003.31 It has been suggested that 
vaccination of 80% of HCWs may be necessary to provide 
herd immunity to prevent healthcare-associated transmis-
sion of influenza.40,47 
The rationale for influenza vaccination of HCWs 
is multifaceted: (1) to reduce influenza infection and ill-
ness in HCWs, (2) to reduce the risk of influenza trans-
mission from an infected HCW to patients and other 
HCWs, (3) to decrease the absenteeism of essential 
HCWs due to influenza infection during community out-
breaks when healthcare facilities are burdened, (4) to 
protect HCWs who have conditions that place them at 
high risk for influenza complications, and (5) to protect 
high-risk household and personal contacts of HCWs. 
These factors, coupled with low HCW vaccination rates, 
led the National Foundation for Infectious Diseases to 
stress the need to improve current HCW vaccination 
programs to protect HCWs and patients, a statement 
that was endorsed by more than 20 stakeholder orga-
nizations and professional associations.48 Additionally, 
multiple groups, including the Society for Healthcare 
Epidemiology of America (SHEA), the Association for 
Professionals in Infection Control and Epidemiology, 
and the CDC’s Healthcare Infection Control Practices 
Advisory Committee, have included HCW influenza vac-
cination compliance as a potential measure for public 
reporting of rates of healthcare-associated infection in 
hospitals.49
Barriers to HCW Acceptance of Influenza 
Vaccine
Many studies have examined the reasons why 
HCWs fail to receive an annual influenza vaccination. 
Concerns about vaccine adverse effects (including fear 
of vaccine-induced illness), fear of injections, perceived 
lack of vaccine efficacy, busy schedules, inconvenience, 
failure of the employer to cover the cost of vaccine, and 
opposition to vaccination in general have all been noted 
in surveys of unvaccinated HCWs (Table 1).50-62 In addi-
tion, healthy HCWs often do not recognize their role in 
influenza transmission to their patients or their families, 
seeing themselves at low risk for influenza infection and 
subsequent morbidity.57 Reasons for declining annual in-
fluenza vaccination may also differ by provider job cat-
egory or setting, signaling a need to tailor educational 
interventions.52,53,58 
Another concern is the self-reported percentage of 
HCWs who work while ill with an influenza-like illness, 
reaching 76.6% in one study.53 In another study, 36.7% of 
housestaff self-reported the development of an influenza-
like illness during the influenza season and worked a mean 
of 2.5 days while ill.55 HCWs, as with other healthy adults, 
may have minimal or no symptoms during their influenza 
infection but still shed the virus, thus potentially exposing 
their patients and colleagues.63 One study during a mild in-
fluenza epidemic noted that 28% of HCWs with serologically 
confirmed influenza infection during the influenza season 
FIGURE 1. Percent of reduction in noted outcomes in healthcare workers 
receiving influenza vaccination.35-39 The two bars noting reductions in patient 
mortality data after healthcare worker vaccination reflect data from two sepa-
rate studies.36,37 All values were statistically significant when compared with 
those for unvaccinated control healthcare workers (P < .05).
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could not recall having any respiratory infection during that 
period.64 
Comprehensive Strategy Recommended by SHEA
Because influenza vaccination is effective in reduc-
ing the transmission of influenza virus and the burden of 
disease, has minimal adverse effects when compared with 
a placebo in randomized trials, and can have a dramatic 
impact on the safety of HCWs and their patients, SHEA 
continues to endorse the National Foundation for Infec-
tious Diseases’ call to action48 and strongly recommends 
that active efforts be made to improve HCW vaccination 
rates. Therefore, we provide recommendations for a mul-
tifaceted program aimed at providing targeted education, 
increasing vaccine access, and emphasizing the ethical 
responsibility HCWs have to protect themselves, their pa-
tients, and their colleagues as part of institutional patient 
and employee safety programs. These recommendations 
apply to all types of healthcare facilities, including acute 
care hospitals, long-term–care facilities, and ambulatory 
care settings, including free-standing clinics, outpatient 
surgery and dialysis centers, physicians’ offices, and 
home care agencies. 
We propose that an effective program to increase 
HCW vaccination rates must (1) provide targeted educa-
tion annually to all HCWs about the severity of influenza, 
particularly among high-risk patients, and the safety of 
influenza vaccination; (2) inform HCWs of the impor-
tance of influenza vaccination in promoting patient and 
employee safety; (3) provide vaccine at no cost and at 
convenient locations and times; (4) recommend that 
HCWs sign a declination each year if they refuse influ-
enza vaccination after participating in an educational 
program or if they have medical contraindications to the 
vaccine (Fig. 2)65; and (5) perform surveillance of rates 
of vaccine uptake by medical unit as well as identification 
of patients with healthcare-associated influenza to assess 
the impact of the vaccination program. 
The educational component of any HCW vaccination 
program must explain the rationale for vaccination of HCWs 
and provide specific messages directed at dispelling myths 
about influenza vaccination, such as the perceived risk of 
post-vaccination influenza-like illness that has not been sub-
stantiated by clinical trials.32,33,38 Vaccination should be con-
venient and easily accessible to minimize the impact on the 
daily activities and duties of HCWs. Proven tools such as 
the use of mobile vaccination carts, continuous educational 
campaigns, visible vaccination of key leaders, off-hours clin-
ics, incentives, and targeted vaccination at departmental or 
staff meetings40,66-72 should all be considered as part of a 
facility’s influenza vaccination program (Table 1). In addi-
tion, influenza vaccine should be provided free of charge 
by the healthcare facility, as is done with other occupational 
safety measures. 
Although the use of active declination to increase 
influenza vaccination rates has not been tested specifi-
cally, it is currently a component of HCW hepatitis B 
vaccination programs as required by the Occupational 
Safety & Health Administration’s Bloodborne Pathogens 
and Needlestick Prevention standard.65 As a result of en-
hanced vaccination programs that include active decli-
nation and the implementation of standard precautions, 
HCW vaccination rates have increased and healthcare-
associated hepatitis B infection rates in HCWs have de-
creased by 98%.73 Active declination of influenza vaccina-
tion as a part of a HCW vaccination program is also one 
of the 30 measured safe practices in the Leapfrog Hospital 
Quality and Safety Survey.74 In addition, multiple states 
TABLE 1
BARRIERS TO HEALTHCARE WORKER INFLUENZA VACCINATION AND RECOMMENDED COMPONENTS OF HEALTHCARE WORKER 
INFLUENZA VACCINATION PROGRAMS
Barrier to HCW Influenza Vaccination Recommended Component of HCW Influenza Vaccination Program
Access to vaccine, inconvenience Off-hours clinics
Use of mobile vaccination carts
Vaccination at staff and departmental meetings
Provision of adequate staff and resources
Cost Provision of vaccine free of charge to HCWs
Concerns for vaccine adverse events, perception of low 
risk for influenza, opposition to the vaccine
Targeted education, including specific information to dispel vaccine myths
Fear of needles Use of live attenuated influenza vaccine for eligible HCWs
Other Strong and visible administrative leadership
Visible vaccination of key leaders
Active declination for HCWs who do not wish to be or cannot be vaccinated
Accurate tracking of individual and unit-based compliance of HCWs with vaccination 
Surveillance for healthcare-associated influenza
HCW = healthcare worker.
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have proposed legislation mandating influenza vaccina-
tion of HCWs in long-term–care facilities and acute care 
hospitals.75 
A recommendation for active declination as a part 
of influenza vaccination programs will result in increased 
workload and recordkeeping for infection control and 
occupational health staff. The annual nature of influenza 
vaccination campaigns, which occur within a few target-
ed weeks each fall, also provides additional challenges; 
however, other types of annual HCW screening may be 
used as models for influenza vaccination campaigns for 
HCWs. Healthcare facility administrators must provide 
ample financial support and human resources to ensure 
the success of their program, which may require seasonal 
hires of information technology, secretarial, and nursing 
personnel to accommodate the demands of the annual vac-
cination campaign. Active declination of the vaccine must 
also be coupled with the other interventions noted above 
designed to increase access to and ease of vaccination. 
During a vaccine shortage, active declination programs 
should be directed only at those HCWs targeted to receive 
vaccine through the facility’s allocation plan based on the 
intensity and duration of contact with patients (see Part II 
below). 
A facility must also be aware of and record influ-
enza vaccination of HCWs from sources other than the 
facility-based vaccination program, such as the HCWs’ 
personal medical provider or alternative employment 
site. In some employment settings, the proportion of 
HCWs receiving vaccination through alternative venues 
may be substantial. A study of medical residents found 
that 64% of housestaff noted as unvaccinated by the fa-
cility’s formal program had actually been vaccinated at 
other sites.76 Offering the vaccine free of charge to all 
HCWs and providing convenient access to the vaccine 
may reduce such off-site vaccination practices. However, 
written documentation of off-site receipt of vaccine is ac-
ceptable. In addition, strategies such as real-time data 
entry may allow facilities to monitor the week-by-week 
uptake of vaccine and the subsequent targeting of units 
with a low rate of compliance.
Facilities should also conduct routine surveillance 
for healthcare-associated influenza to assess the impact of 
the HCW vaccination program. As cases of healthcare-as-
sociated influenza may be unrecognized unless they are 
part of a larger unit- or facility-wide outbreak, prospective 
surveillance has been used at some facilities and has been 
effective in detecting smaller outbreaks of infection.40,77 
The degree of surveillance, definitions for influenza-like 
illness, and the need for laboratory confirmation of influ-
enza, however, may depend on the size and available re-
sources of the facility. Other measures of the impact of a 
HCW vaccination program are less reliable. For example, 
tracking reports of influenza-like illness in HCWs is dif-
ficult to perform accurately and monitoring absenteeism 
may underestimate vaccine effect given the high reported 
percentage of HCWs who work while ill.55 In addition, be-
cause the majority of influenza-like illness is not influenza, 
tracking influenza-like illness alone is likely to mask the 
benefits of vaccination.
Summary Recommendations for HCW Influenza 
Vaccination
1. For the safety of HCWs and patients, all HCWs 
should receive influenza vaccine annually unless they have 
a contraindication to the vaccine or actively decline vaccina-
tion.
2. All healthcare facilities should provide annual 
multifaceted programs to actively promote vaccination of 
HCWs.
3. Influenza vaccination programs should contain the 
following elements:
a. Targeted education about the severity of influ-
enza illness, particularly in high-risk patients. 
b. Targeted education about vaccine efficacy and 
safety as well as dispelling of vaccine myths.
c. Administrative support and leadership.
d. Provision of vaccine at no cost to HCWs.
e. Improved access to vaccine (eg, via mobile carts 
and off-hours clinics).
f. Active declination policy for HCWs who do not 
want or cannot receive influenza vaccine.
4. All healthcare facilities should accurately track and 
record HCW vaccination rates, including vaccinations ob-
tained outside of the formal facility program, to assess the 
effectiveness of the vaccine program. These data should 
include compliance for individual HCWs and unit-specific 
rates. 
5. Each facility should have a surveillance system for 
healthcare-associated influenza to assess the impact of its 
vaccination program. 
PART II: ALLOCATION OF INFLUENZA 
VACCINE TO HCWS DURING A 
SHORTAGE
In the fall of 2004, the license of one of the two 
main manufacturers of inactivated trivalent influenza vac-
FIGURE 2. Example of an active declination form for healthcare worker 
influenza vaccination programs (adapted from Appendix A of the Occu-
pational Safety & Health Administration’s Bloodborne Pathogens and 
Needlestick Prevention65).
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cine was suspended in the United States, resulting in a 
widespread vaccine shortage. The CDC recommended 
prioritized delivery of available vaccine to those at great-
est risk for influenza complications as well as to HCWs 
caring for these individuals.78 Delivery of vaccine in 
2004–2005 was sporadic, with some areas reporting a vac-
cine surplus at the end of the influenza season. Although 
the total number and timing of distribution of available 
doses for the 2005–2006 season is currently unknown, 
the CDC anticipates that four manufacturers will supply 
influenza vaccine (three that produce trivalent influenza 
vaccine and one that produces the live attenuated vac-
cine).79,80 However, a potential shortage of influenza vac-
cine in Europe for the coming season has already been 
reported.81 
As disruptions in the manufacture or distribution of 
inactivated influenza vaccine have occurred in three of the 
past five seasons in the United States,78,79,82 guidance is re-
quired about allocation of available vaccine to HCWs during 
a delay or shortage of vaccine. Detailed recommendations 
for allocation of influenza vaccine to patients during a vac-
cine shortage have been published, but no stratification 
within the group of HCWs was included.79 
Developing guidance on vaccine allocation to 
HCWs is a challenging task, as one specific strategy 
may not be feasible for all healthcare facilities. For any 
healthcare facility, protection of patients and having 
sufficient numbers of HCWs to care directly for those 
patients is a primary goal. Allocation criteria should be 
evidence based and adhere to the key ethical principles 
of nonmaleficence (avoiding the causation of harm), 
beneficence (providing benefits and balancing benefits 
against risk and costs), and justice (the fair distribution 
of benefits, risks, and costs).83 Whereas the decisions 
of healthcare providers are often focused on a single pa-
tient, decisions regarding allocation of scarce resources 
such as influenza vaccine must focus on the well-being 
of the population. Furthermore, any allocation strategy 
must be practical, transparent to engender trust and al-
low HCWs to understand the rationale for allocation, 
and prompt in delivering available vaccine to HCWs.
In addition, vaccine allocation strategies must also 
consider several key factors:
Routes of Influenza Transmission. Although 
airborne transmission of influenza has been suspected in 
animal and observational studies and may occur under spe-
cific conditions of confined air spaces with suboptimal air 
circulation,84-86 the predominant route of transmission of 
influenza virus is thought to be via large respiratory drop-
lets (> 10 µm) that may be propelled a short distance (up 
to 3 feet) by sneezing or coughing but that do not remain 
suspended in the air.87,88 Influenza transmission has been 
prevented by using droplet precautions.89 Thus, prioritizing 
vaccination for HCWs according to the nature, degree, and 
duration of patient contact may be necessary during a vac-
cine shortage. Prioritizing those HCWs with close (within 
3 feet), prolonged (several minutes), and repeated patient 
contact would target those most at risk of exposure to and 
transmission of influenza, potentially maximizing the im-
pact of HCW vaccination with a limited vaccine supply. 
Degree of HCW Contact With Patients at 
High Risk for Influenza Complications. Although 
all unvaccinated patients are at risk of contracting in-
fluenza from an infected HCW, during a severe vaccine 
shortage it may be necessary to allocate vaccine to those 
HCWs who have the most frequent and intense contact 
with patients at greatest risk for complications and ad-
verse outcomes. 
Need to Cover Essential HCWs and Servic-
es. Certain functions and services of a healthcare facility 
are vital for the care of patients, the health of the com-
munity, and the functioning of the institution. HCWs per-
forming such services may be prioritized for vaccination 
to prevent disruption of these services. For example, the 
only level-1 trauma center in a community would need 
to ensure available trauma services and, therefore, may 
place essential trauma staff high on the priority list for 
vaccination. 
Exposure Risk in Areas of High Patient Traf-
fic in a Facility. Areas with a large volume of patients 
not yet identified as having influenza (such as emergency 
departments, high-volume acute care clinics, and active 
units with high occupancy and rapid patient turnover) can 
increase the risk of HCW exposure to infectious patients 
and the subsequent transmission to a larger number of pa-
tients. Vaccinating HCWs in these high traffic areas may 
also provide the largest impact with available vaccine sup-
plies.
Areas Where Infected Patients Are Less Like-
ly to Be Properly and Promptly Isolated. HCWs in 
areas where exposure to patients with influenza can occur 
before these patients can be placed on droplet precautions, 
such as emergency department staff, acute care clinic em-
ployees, and emergency first responders, may be at greater 
risk of contracting influenza as opposed to HCWs in units 
where patients with influenza are more likely to be isolated 
prior to exposure. 
Use of the Live Attenuated Influenza Vac-
cine in Eligible HCWs. An important alternative to 
the inactivated trivalent influenza vaccine is the live at-
tenuated influenza vaccine, which is licensed for use in 
healthy individuals 5 to 49 years old. A theoretical con-
cern about the use of live attenuated influenza vaccine 
has been the possibility for secondary transmission of 
the vaccine virus; however, the live attenuated influenza 
vaccine virus is modified to limit growth in temperatures 
higher than 37°C (similar to the temperature of the lower 
airways). Therefore, it is unlikely that the vaccine virus 
would survive or replicate in the airways. The vaccine vi-
rus has also been modified into a nonvirulent strain that 
cannot cause disease in the event of inadvertent trans-
mission.90 For effective transmission of live attenuated 
influenza vaccine virus to a vulnerable patient, the recipi-
ent must shed the virus in a large enough quantity, the 
shed virus must lose its inability to replicate at higher 
temperatures, and the virus must revert back to the wild 
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type and produce disease.91 This chain of events is ex-
ceedingly unlikely based on virologic data from individu-
als who received live attenuated influenza vaccine.91-93 
The quantity of virus shed in recently vaccinated individ-
uals is well below the known infective dose of influenza 
virus,92 genetic reversion to the virulent wild type virus 
has never been noted, and, despite an increasing use of 
live attenuated influenza vaccine, transmission of vaccine 
virus has been reported in only one individual, who had 
no symptoms.94 
To allocate limited supplies of inactivated trivalent 
influenza vaccine during a shortage, use of live attenuated 
influenza vaccine in selected HCWs is prudent, thus sav-
ing trivalent influenza vaccine for those who cannot receive 
live attenuated influenza vaccine due to comorbid illness 
or work in a restricted unit. Due to the theoretical risk of 
transmission of live virus, the CDC advises that HCWs who 
receive live attenuated influenza vaccine avoid contact with 
severely immunosuppressed patients who require care in a 
protective environment (eg, hematopoietic stem cell trans-
plant recipients hospitalized in a room with positive airflow 
such as in a myelosuppression or bone marrow transplant 
unit) for only 7 days after vaccination because shedding of 
virus has not been detected in adults after this time.31,92,95 
Use of Non-Vaccine Measures to Prevent In-
fluenza. During any influenza season, measures other 
than vaccination are also important to reduce the risk of 
healthcare-associated transmission of influenza. However, 
during a vaccine shortage, these measures become even 
more essential for the protection of HCWs and patients. 
These measures include adhering to hand hygiene prac-
tices, using respiratory hygiene and cough etiquette (ie, 
use of a surgical mask and placement of patients with 
respiratory symptoms at least 3 feet apart from other pa-
tients in the waiting room, use of tissues to contain na-
sal secretions, and use of an alcohol-based hand hygiene 
agent after hand contamination with nasal secretions),96 
and screening of visitors to high-risk patient areas (eg, 
intensive care or oncology units) with exclusion of sick 
visitors from the facility.95 HCWs with a febrile respiratory 
illness should be placed on sick leave. Afebrile HCWs 
with acute respiratory symptoms consistent with a viral 
infection should be excluded from contact with patients 
at the highest risk. However, if they are able to contain 
their respiratory secretions and control coughing, the use 
of a surgical mask and consistent hand hygiene adherence 
while performing patient care activities will reduce the 
risk of transmission. Antiviral chemoprophylaxis may also 
be used to prevent infection in individuals at risk during 
community or facility outbreaks.31 
Methods to Increase the Available Supply of In-
activated Trivalent Influenza Vaccine. Other options 
to increase the available inactivated influenza vaccine supply 
have been examined and are promising, such as intradermal 
injection of trivalent influenza vaccine and reducing the dose 
for intramuscular administration in otherwise healthy young 
adults.97-99 However, further data are needed before making 
firm recommendations based on these strategies. 
HCWs Who Are Not in a Priority Group Dur-
ing a Vaccine Shortage. This group of HCWs should 
receive information about non-vaccine strategies for the 
prevention of influenza as well as community-based sites 
where vaccine might be available. HCWs who have not 
been placed in a priority subgroup for receiving vaccine 
during a shortage (eg, direct patient care) but have been in-
cluded in a CDC-defined patient risk group by virtue of age, 
pregnancy, or an underlying illness should be encouraged 
to obtain vaccine via their local healthcare provider or local 
health department. A process should also be developed to 
rapidly inform unvaccinated HCWs as priorities change and 
vaccine becomes available so that they can be expeditiously 
vaccinated. If vaccine supply is adequate at the local facil-
ity, vaccination at the facility’s occupational health service 
is appropriate.
Flexibility to Address the Unique Needs of 
a Facility. Because every healthcare facility has unique 
needs, services, and idiosyncrasies, any HCW vaccine 
allocation strategy must be adaptive to fit to the local 
needs of the institution. A multidisciplinary facility advi-
sory board composed of institutional leaders in key areas 
(eg, infectious diseases, occupational medicine, infection 
control, pediatrics, geriatrics, pharmacy; the institutional 
ethics committee; and administration) may be helpful to 
determine the facility’s high-risk areas and populations as 
well as to allocate vaccine supplies as they become avail-
able. Facilities may also develop novel tools to assist in 
vaccine allocation. During the 2004–2005 shortage, one 
institution required HCWs to complete a facility-specific 
questionnaire that used influenza risk factors, Occupa-
tional Safety & Health Administration respirator medical 
screening, and an assessment of the degree of patient con-
tact to devise an index score that was used to determine 
vaccine delivery. This resulted in a vaccination rate higher 
than historical averages.100
A Proposed Tiered Approach to Vaccine 
Allocation
Using the recommendations noted above, we pro-
pose a tiered distribution of influenza vaccine for HCWs 
in the event of inadequate supply. The highest priority 
should be given to HCWs with the greatest risk of expo-
sure to the patients at highest risk for influenza complica-
tions (Table 2). During a vaccine shortage, HCWs who 
have close (within 3 feet), prolonged (several minutes), 
and repeated contact with the patients at the highest risk 
comprise the first tier (1A). For example, a specific fa-
cility may elect to vaccinate intensive care unit nurses 
and respiratory therapists before other staff who have 
a lesser degree of close patient contact to maximize the 
benefits from a limited vaccine supply. As vaccine sup-
plies increase, other HCWs working with high-risk pa-
tients, essential HCWs, and HCWs in areas of high pa-
tient traffic should be vaccinated (tiers 1B and 1C). With 
larger supplies, all HCWs with patient care responsibili-
ties should receive the vaccine (tier 2). To protect HCWs 
who are not vaccinated, as well as those who are, and 
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their patients, other strategies to reduce transmission 
should also be actively promoted and used. It must be ac-
knowledged that during a severe vaccine shortage, avail-
able supplies may not be sufficient to cover every HCW 
in the highest priority group. Facility leaders, together 
with a multidisciplinary advisory panel, must base their 
decisions for vaccine allotment on the principles outlined 
above with clear communication of the rationale to all 
HCWs in the organization. This process must be applied 
uniformly and must be transparent, with the rationale for 
allocation decisions readily apparent. Finally, this tiered 
system should be applied only in the event of a vaccine 
shortage; during non-shortage periods, facilities should 
follow the CDC recommendations and offer influenza 
vaccine to all HCWs.31
Summary Recommendations for the Allocation 
of Vaccine During a Shortage
1. Vaccine allocation strategies must focus primarily 
on the protection of patients at highest risk for complica-
tions from influenza.
2. Allocation strategies must use data on influenza 
transmission risk to identify those HCWs at greatest risk of 
transmitting influenza to high-risk patients.
3. During times of limited supply, the tiered strategy 
presented in Table 2 should be followed.
4. Live attenuated influenza vaccine should be used in 
eligible HCWs to conserve trivalent influenza vaccine sup-
plies.
5. As during times when vaccine supplies are am-
ple, healthcare facilities should continue to emphasize 
non-vaccine measures (infection control precautions, 
respiratory hygiene and cough etiquette, and chemo-
prophylaxis) for the prevention of transmission of influ-
enza, as well as other respiratory viruses, among HCWs 
and patients.
CONCLUSIONS
As outlined above, vaccination of HCWs is a key mea-
sure in the prevention of healthcare-associated influenza. 
HCW vaccination programs must be multifaceted, evidence 
driven, and focused on maximizing the effect of available 
vaccine from a population standpoint. Although allocation 
decisions during a vaccine shortage can be challenging, 
using principles of influenza transmission, identifying the 
unique needs of a facility, and applying effective, non-vac-
cine interventions can optimize the impact of a HCW vac-
cination program. 
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